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Abstract
Genetic variability across the SNCA locus has been repeatedly associated with susceptibility to sporadic Parkinson’s disease
(PD). Accumulated evidence emphasizes the importance of SNCA dosage and expression levels in PD pathogenesis.
However whether genetic variability in the SNCA gene modulates the risk to develop sporadic PD via regulation of SNCA
expression remained elusive. We studied the effect of PD risk-associated variants at SNCA 59 and 39regions on SNCA-mRNA
levels in vivo in 228 human brain samples from three structures differentially vulnerable to PD pathology (substantia-nigra,
temporal- and frontal-cortex) obtained from 144 neurologically normal cadavers. The extensively characterized PD-
associated promoter polymorphism, Rep1, had an effect on SNCA-mRNA levels. Homozygous genotype of the ‘protective’,
Rep1-259 bp allele, was associated with lower levels of SNCA-mRNA relative to individuals that carried at least one copy of
the PD-risk associated alleles, amounting to an average decrease of ,40% and .50% in temporal-cortex and substantia-
nigra, respectively. Furthermore, SNPs tagging the SNCA 39-untranslated-region also showed effects on SNCA-mRNA levels
in both the temporal-cortex and the substantia-nigra, although, in contrast to Rep1, the ‘decreased-risk’ alleles were
correlated with increased SNCA-mRNA levels. Similar to Rep1 findings, no difference in SNCA-mRNA level was seen with
different SNCA 39SNP alleles in the frontal-cortex, indicating there is brain-region specificity of the genetic regulation of
SNCA expression. We provide evidence for functional consequences of PD-associated SNCA gene variants in disease relevant
brain tissues, suggesting that genetic regulation of SNCA expression plays an important role in the development of the
disease.
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Introduction
Alpha-synuclein (SNCA) (Ensembl: ENSG00000145335; OMIM,
Online Mendelian Inheritance in Man: MIM 163890) was the first
gene found to be involved in Parkinson’s disease (PD[MIM
168600]). SNCA aggregates have been identified within Lewy
bodies, the pathological hallmark of PD [1]. Also, mutations [2–4]
and copy number variations [5–9] in the SNCA gene have been
identified in a few families with an early onset, autosomal dominant
form of PD. Furthermore, accumulated evidence suggests that
elevated levels of wild type SNCA lead to neuronal dysfunction and
are sufficient to cause early onset familial PD. Genomic triplication
of the region containing SNCA was shown to result in four fully
functional copies of SNCA and 2-fold over-expression of SNCA
mRNA and protein and a highly penetrant early-onset PD
phenotype with cognitive impairment and autonomic dysfunction
[10,11]. Similarly, duplications of the wild-type SNCA gene result in
a 1.5-fold elevation of SNCA expression and a slightly later onset of
heritable PD that is characterized by a lower penetrance rate and a
‘milder’ phenotype than for the triplication [6–9], demonstrating
the dose-dependent effect of SNCA on disease presentation.
Furthermore, elevated levels of SNCA-mRNA have been reported
in midbrain tissues [12] and in individual substantia nigra
dopaminergic neurons from sporadic PD post mortem brains
compared to controls[13]. These observations emphasize the
importance of SNCA dosage and expression levels in PD
pathogenesis.
Several association studies have demonstrated that genetic
variability across the SNCA locus is associated with susceptibility to
sporadic PD [14–18]. Based on HapMap data SNCA has two
major linkage disequilibrium (LD) blocks, a 59 block that extends
to the promoter-enhancer region and a 39 block that comprises the
39untranslated-region (UTR) and the 39 region of the gene
[15,18]. These studies confirmed the association of variants within
both SNCA 59 and 39 LD-blocks with PD-risk, suggesting that the
genetic regulation of SNCA expression might be mediated through
different molecular mechanisms (transcriptional and post tran-
scriptional) and could have an important role in the development
of the disease. Previously, we extensively characterized the best
confirmed associated genetic variation, Rep1, a polymorphic
nucleotide repeat site located ,10 kb upstream of the SNCA
transcription start site [19,20]. Using a reporter assay in a
transiently transfected neuronal cell line [21,22] and a transgenic
mouse model [23], we demonstrated that SNCA-Rep1 had a
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model systems, the extended risk allele showed increased
expression of the reporter construct and the human transgene,
respectively; while the shorter PD-‘protective’ allele was associated
with lower expression levels [21,22].
Here we aim to reveal the functional consequence of genetic
variations in the SNCA genomic region. We studied the effect of
the Rep1 variant as well as other PD risk-associated variants on
SNCA-mRNA steady state levels in vivo in three human brain
structures differentially vulnerable to PD; i.e. frontal cortex,
temporal cortex and mid-brain including the substantia nigra (SN).
Our comprehensive analysis was performed using post mortem
matched brain tissues from unaffected individuals to directly assess
the genetic contribution to the regulation of SNCA expression,
avoiding other confounding factors arising from the neurodegen-
eration associated with PD.
Results
Effect of secondary (non-genetic) variables on
SNCA-mRNA level
SNCA-mRNA fold levels (SNCA/SYP) were measured in 228
brain tissue samples obtained from 144 subjects (83% white,
56.5% males; Table 1). First, we assessed the correlation of SNCA-
mRNA expression with confounding factors that might affect
RNA levels. All midbrain including substantia nigra (SN) samples
were obtained from white individuals. SNCA mRNA folds levels in
midbrain including SN (n=34) were not correlated with sex
(P=0.187), age (P=0.735), or PMI (p=0.177). Similarly, no
correlations of SNCA-mRNA levels were observed in temporal
(n=77) and frontal cortex (n=117) with sex (P=0.49, 0.46), race
(P=0.59, 0.14), age (P=0.35, 0.742), or PMI (P=0.85, 0.7).
Next, the effect of specificity of the brain tissue region on SNCA
expression was assessed. To carry out this analysis we used
matched samples, i.e. samples of different brain structures
obtained from the same cadaver. Frontal cortex showed
significantly lower levels of SNCA-mRNA compared with
midbrain including SN (n=9; P=0.001) and temporal cortex
(n=75; P=1.6610
29). The average SNCA-mRNA fold levels
observed in the frontal cortex samples was approximately 50% less
from the average SNCA-mRNA fold levels detected in the
temporal cortex and in the midbrain including SN of the same
individuals. Comparison of SNCA mRNA fold levels between
matched samples of temporal cortex and midbrain including SN
revealed no differences (n=7, P=0.37). Furthermore, we were
able to carry out a direct comparison of all three brain regions in 7
cadavers from whom all brain regions were available, showing that
the average fold expression levels of SNCA-mRNA are similar in
midbrain including SN and temporal cortex and nearly twice the
average fold levels observed in the frontal cortex (Figure 1). Thus,
Table 1. Demographic description of the brain samples.
Subjects Tissues FC TC SN
Subjects with
multiple tissues FC+TC+SN FC+TC FC+SN
Total no. 144 228 117 77 34 77 7 68 2
White (%) 83.0 81.2 72.7 100 100 72.1 100
Male (%) 56.5 53.5 51.4 53.6 0 50.0 0
Age at Death
(mean6S.E.M)
65.1618.1 69.3616.9 69.0617.6 55.6618.1 82.465.8 69.8617.2 81.564.5
PMI (mean6S.E.M) 15.266.8 15.467.5 13.367.0 13.064.2 7.564.9 13.367.1 1462.0
FC- frontal cortex, TC-temporal cortex, SN-substantia nigra. PMI- post mortem interval.
doi:10.1371/journal.pone.0007480.t001
Figure 1. Average fold expression of SNCA-mRNA in three matched brain regions obtained from the same subjects (n=7). Fold levels
of SNCA-mRNA were assayed by real-time RT-PCR using TaqMan technology and calculated relative to the geometric mean of SYP- and ENO2- mRNAs
reference control using the 2
2DCt method. The bar graph presents the average of SNCA-mRNA fold expression (mean6S.E.M) of the 7 subjects for
each brain region. SN-substantia nigra; TC-temporal cortex; FC- frontal cortex.
doi:10.1371/journal.pone.0007480.g001
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expression levels in the substantia nigra.
Effect of variants in the 59 region of SNCA on SNCA-
mRNA levels in different brain tissues
We studied the effect of variants in the promoter enhancer
region of SNCA on SNCA mRNA levels. Three polymorphisms
were tested: two SNCA 59 region tagging SNPs (rs2619363 and
rs2583988) and Rep1 (Figure 2).
All samples were genotyped for both the rs2619363 and
rs2583988 SNPs; Table 2 summarizes the allele frequencies in
our samples. The tagging SNPs rs2619363 and rs2583988 in the
promoter of the SNCA gene did not show any correlation to SNCA
mRNA in the midbrain including SN (P=0.58, 0.92) the temporal
cortex, (P=0.68, 0.95) or the frontal cortex (P=0.68, 0.84).
We then tested for correlation with Rep1 genotypes. A
summary of Rep1 allele frequencies of the studied samples is
presented in Table 3. Analysis of the temporal cortex (n=77)
indicated that individuals homozygous for the PD-‘protective’
genotype 259/259 (n=8) had lower SNCA-mRNA levels than
individuals carrying the 259/261, 261/261, 259/263, 261/263
and 263/263 genotypes (Figure 3A; P=0.02). In the temporal
cortex Rep1 259/259 demonstrated an average 0.59 fold SNCA-
mRNA expression level compared with an average 1.00, 0.94,
0.95, 0.83 and 0.90 fold expression level of SNCA-mRNA in the
five other genotypes 259/261, 261/261, 259/263, 261/263 and
263/263 genotypes carriers, respectively (Figure 3A). From these
results we calculated that individuals who carried two copies
of the PD ‘protective’ Rep1-259 bp, had reduced levels of human
SNCA-mRNA, amounting to a nearly 40% decrease relative to
individuals that carried at least one copy of the PD-risk associated
alleles. Similarly, in the midbrain including SN samples (n=34) a
50–65% decrease in the average expression level of SNCA-mRNA
was observed with the 259/259 genotype (n=3) when compared
to each of the other Rep1 genotypes (Figure 3B). This reduction
effect of the 259/259 genotype did not show, however, a trend
towards significance which might be explained by the small size of
the group and the large variability in SNCA-mRNA levels within
each genotype group (resulting from the neuronal cell heteroge-
neity of the mid brain/substantia nigra tissue)[12]. In contrast, no
significant correlation of the Rep1 site with SNCA-mRNA levels
was identified in the frontal cortex (n=117; P=0.91), suggesting
that Rep1 might affect SNCA expression in a brain-region specific
manner (Figure 3C). A summary of the results is listed in Table 4.
Effect of SNPs in the 39 region of SNCA on SNCA-mRNA
levels in different brain tissues
The effect of the SNCA 39 region on SNCA mRNA levels was
tested with three SNPs: the rare rs17016074 and the two 39 region
common tagging SNPs rs356219 and rs365165 (Figure 1). All
samples contained the rs356219, rs365165, and rs17016074 SNP
genotypes and the allele frequencies in our study group are
summarized in Table 2. Genotypes of SNP rs356219 (G/A)
showed an effect on SNCA mRNA levels in temporal cortex
(P=0.013) and midbrain including SN tissue (P,0.05) (Figure 4 A
and B). In the temporal cortex the homozygous rs356219
‘protective’ AA genotype (n=29) showed higher expression levels
Figure 2. A schematic representation of the human SNCA gene with the relative positions of the markers. Organization of the human
SNCA locus: translated exons, wide black solid boxes; 59 and 39UTR, narrow black solid boxes; introns and intergenic regions, grey line. The relative
positions of the genetic variants are indicated above, asterisks designate variants that were associated with SNCA-mRNA.
doi:10.1371/journal.pone.0007480.g002
Table 2. Rep1 allele frequencies of the study group.
Rep1
All
No.(%)
Caucasians
No.(%)
Maraganore et al. (JAMA, 2007)
No.(%)
259 88(0.31) 71(0.304) 1413(0.27)
261 172(0.606) 151(0.645) 3579(0.68)
263 23(0.08) 12(0.051) 312(0.06)
265 1(0.004) 0 0
No.- total number of alleles (2 per individual); % allele frequency.
doi:10.1371/journal.pone.0007480.t002
Table 3. SNPs analyzed in the study with allele frequencies.
SNP Total No./MAF Caucasians No./MAF CEPH{ No./MAF
rs2583988 69/0.241 63/0.272 102/0.255
rs2619363 72/0.25 64/0.274 112/0.24
rs17016074 9/0.031 4/0.017 112/0
rs365165 128/0.448 98/0.419 0.37*
rs356219 120/0.417 88/0.376 112/0.411
No.- total number of alleles (2 per individual); MAF- the minor allele frequency.
{HapMap data base. *MAF reported in PD-SNCA association studies.
doi:10.1371/journal.pone.0007480.t003
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amounting to a nearly 40% increase (Figure 4A). In the substania
nigra, the homozygous AA and the heterozygous GA genotypes
(n=12, 16) correlate with higher SNCA mRNA levels than the risk
genotype GG (n=6) (Figure 4B). In the frontal cortex, on the
contrary, no correlation was identified between SNCA mRNA
Figure 3. Effect of the SNCA-Rep1 promoter genotypes on human SNCA-mRNA expression levels in human brains. Individuals were
genotyped for Rep1. Three brain regions were analyzed: temporal cortex (A), midbrain including SN (B) and frontal cortex (C). In each brain region fold
levels of human SNCA-mRNA were assayed by real-time RT-PCR using TaqMan technology and calculated relative to human SYP-mRNA reference control
using the 2
2DCt method. (A) Analysis of the temporal cortex showed that the protective genotype 259/259 correlates with lower SNCA-mRNA levels then
thefiveothergenotypes(P=0.02).TheassociationtrendwasconfirmedinasubsetofsamplesusingalsotheGAPDHandENO2referencegenes(TableS2).
(B)InthemidbrainincludingSNthe259/259correlates,withlowerSNCA-mRNAlevels.(C)NocorrelationsofRep1genotypeswithSNCA-mRNAlevelswere
detected in the frontal cortex. For each genotype the box plot represents the analysis performed using all brain samples available from the specific brain
region, each of which was analyzed twice independently, each time in duplicate. The average values are presented in ‘X’. The box plot shows the median
(horizontal line inside the box) and the 25
th and 75
th percentiles (horizontal borders of the box). The range between the 25th and 75th percentiles is the
interquartile-range (IQR). The whiskers show the minimal and maximal values inside the main data body.
doi:10.1371/journal.pone.0007480.g003
Table 4. Summary of the genetic correlations between genetic variants at SNCA locus and SNCA-mRNA levels.
FC TC SN
59region Rep1 = 259/259,259/261, 261/261, 259/263, 261/263, 263/263 *259/259,259/261, 261/261, 259/263, 261/263, 263/263
rs2583988 == =
rs2619363 == =
39region rs17016074 =* A A ,GA,GG *AG,GG
rs365165 =A A .GA, GG AA,GA.GG
rs356219 =A A .GA, GG AA,GA.GG
‘=’ no correlation, *no trend towards significance, FC- frontal cortex, TC-temporal cortex, SN-substantia nigra.
doi:10.1371/journal.pone.0007480.t004
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were also correlated with SNP rs365165 (G/A) in temporal cortex
(Figure 5A, P,0.05) and midbrain including SN (Figure 5B,
P,0.05), following the same correlations of genotypes to SNCA
mRNA fold expression (Table 4); while no correlation was
observed in the frontal cortex (Figure 5C), similar to the results
obtained for the downstream SNCA 39 SNP. Thus, as expected
based on the high LD between these SNPs, the results observed for
SNP rs365165 supported the findings of SNP rs356219 (Table 4).
Of note the magnitude of the SNPs effect on SNCA-mRNA fold
expression was larger for SNP rs356219. Analysis of the rare
(,5%) rs17016074 suggested a possible effect of the minor allele
on SNCA mRNA reduction, since the homozygous AA (n=1 of 77)
had a lower level of SNCA mRNA in the temporal cortex and the
heterozygous AG (n=1 of 34) revealed a lower level in the
midbrain including SN, which will need to be explored with a
larger group (data not shown). The frontal cortex region did not
show a significant correlation with SNCA mRNA folds levels with
any of the genotypes at the 39 region SNPs. A summary of the
results is listed in Table 4.
Discussion
Finding interesting correlations between genetic variants and
gene expression levels does not necessarily require a comparison
between tissues from both affected cases and controls. Significant
differences in gene expression levels were also shown to be
associated with different genotypes in human tissues of unaffected
individuals [24,25]. Identification of such genetic expression effects
in a disease relevant tissue could provide important information
for determining which variants to pursue in functional studies and
which will further our understanding of the underlying biology of
associations with the disease of interest. We previously reported
differences in SNCA-mRNA expression levels between PD cases
and controls[12]. However, in this current report, we analyzed
unaffected brains, which allow us to overcome methodological and
Figure 4. Effect of SNP rs356219, 39region genotypes, on human SNCA-mRNA expression levels in human brains. Individuals were
genotyped for SNP rs356219. Three brain regions were analyzed: temporal cortex (A), midbrain including SN (B) and frontal cortex (C). In each brain
region fold levels of human SNCA-mRNA were assayed by real-time RT-PCR using TaqMan technology and calculated relative to human SYP-mRNA
reference control using the 2
-DCt method. (A) Analysis of the temporal cortex showed that the protective genotype AA correlates with higher SNCA-
mRNA levels than the GA and GG genotypes (P=0.013). The association trend was confirmed in a subset of samples using also the GAPDH and ENO2
reference genes (Table S2). (B) In the midbrain including SN the AA and AG genotypes correlate with higher SNCA-mRNA levels compared with the
GG risk genotype (P,0.05). (C) No correlations of SNP rs356219 genotypes with SNCA-mRNA levels were detected in the frontal cortex. For each
genotype the box plot represents the analysis performed using all brain samples available from the specific brain region, each of which was analyzed
twice independently, each time in duplicate. The average values are presented in ‘X’. The box plot shows the median (horizontal line inside the box)
and the 25
th and 75
th percentiles (horizontal borders of the box). The range between the 25th and 75th percentiles is the interquartile-range (IQR).
The whiskers show the minimal and maximal values inside the main data body.
doi:10.1371/journal.pone.0007480.g004
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particularly neuronal loss, along with other pathologic processes
accompanying neurodegeneration that may influence expression.
Following this approach, we looked for variations in SNCA
expression in the brains of unaffected people (age matched to
late-onset PD). Specifically, in the present study we focus on
genetic regulation of RNA. Therefore, we looked for variations in
SNCA mRNA levels and tested for association with PD-associated
variants positioned within putative regulatory regions for RNA
expression: 1) the 59 region of the gene which presumably
influences transcription and 2) the 39 UTR and 39 of the gene that
most likely affects post-transcriptional regulation. All variants
chosen for the present study had been repeatedly reported to
confer increased risk for developing PD [14–18]. The five
analyzed SNPs are located within evolutionary highly conserved
regions, and the two 59 SNPs were also in or very close to potential
binding sites for transcription factors (data not shown).
In the 59 region we found that, among the polymorphic loci
tested, only variation at the Rep1 locus was responsible for
differences seen in SNCA-mRNA levels. Previously, we extensively
characterized the functional significance of the PD-associated
Rep1 polymorphic site [26–29] and its contribution to the
transcriptional regulation of SNCA in an in vitro cell-based system
and in vivo using a transgenic mouse model [21,22,30]. Recently,
Fuchs and colleagues reported Rep1’s effect on SNCA protein
levels in human blood, but failed to detect an effect in brain
samples (N control subject=24) [31]. Here using a much large sample
size (N control subject=144) we demonstrate for the first time the
regulatory effect of Rep1 alleles in vivo in human brain structures
relevant to the disease providing further direct, functional evidence
for the reported genetics associations; i.e. in PD-affected brain
regions the ‘protective’ genotype correlated with lower SNCA-
mRNA levels compared with all the other genotypes carrying one
or two PD-risk alleles (261 and 263) [18,26–29]. The direction of
the Rep1 alleles’ effect on SNCA-mRNA levels is consistent with
our previous observations using both a cell-based reporter
system[22] and a mouse model [23]. Furthermore, our finding
lends support to the general hypothesis that an increase in the
Figure 5. Effect of SNP rs365165, 39region genotypes, on human SNCA-mRNA expression levels in human brains. Individuals were
genotyped for SNP rs365165. Three brain regions were analyzed: temporal cortex (A), midbrain including SN (B) and frontal cortex (C). In each brain
region fold levels of human SNCA-mRNA were assayed by real-time RT-PCR using TaqMan technology and calculated relative to human SYP-mRNA
reference control using the 2
-DDCt method. (A) Analysis of the temporal cortex showed that the protective genotype AA correlates with higher SNCA-
mRNA levels than the GA and GG genotypes (P,0.05). (B) In the midbrain including SN, the AA and AG genotypes correlate with higher SNCA-mRNA
levels compared with the GG risk genotype (P,0.05). (C) No correlations of SNP rs365165 genotypes with SNCA-mRNA levels were detected in the
frontal cortex. For each genotype, the box plot represents the analysis performed using all brain samples available from the specific brain region,
each of which was analyzed twice independently, each time in duplicate. The average values are presented in ‘X’. The box plot shows the median
(horizontal line inside the box) and the 25
th and 75
th percentiles (horizontal borders of the box). The range between the 25th and 75th percentiles is
the interquartile-range (IQR). The whiskers show the minimal and maximal values inside the main data body.
doi:10.1371/journal.pone.0007480.g005
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‘idiopathic’ PD phenotype, while decreased SNCA levels protect
from this devastating disease.
In the 39 region, we found evidence for a regulatory role for all
tested SNPs. In contrast to the Rep1 effect, however, the
‘protective’ genotype at the 39 region defined by each of the
common tagging SNPs is associated with higher SNCA-mRNA
levels in disease affected brain tissues (midbrain including SN and
temporal cortex). With both of the common 39 region tagging
SNPs, rs356219 and rs365165, the ‘protective’ AA genotype
correlated with higher SNCA-mRNA in the temporal cortex, while
both the homozygous ‘protective’ and the heterozygous genotypes
(AA and GA) correlated with higher mRNA levels in the midbrain
including SN. In general, our findings are in agreement with a
recent smaller scale study reporting that the protective rs356219
genotype (AA) is accompanied by higher mRNA levels in the
cerebellum, whereas the heterozygous genotype (GA) correlated
with the higher mRNA levels in the midbrain including SN. The
subtle differences from this previous study might be from the result
of the smaller sample size studied [31]. Although these findings
run contrary to the conventional hypothesis that lower SNCA
expression confers PD-protection, it might be that rs356219,
rs365165, or any other SNP in the 39 LD block (extended to
include intron 4), exerts a regulatory effect not simply by changing
total SNCA-mRNA levels but by a different molecular mechanism,
such as splicing, to change the relative levels of the different splice
forms (e.g., NACP140/112). For example, it was suggested that
exon 5 deletion (NACP112) result in enhanced aggregation due to
a significant shortening of the unstructured C-terminus[32,33].
Thus, one can speculate that although the protective genotype led
to an increase in the overall SNCA-mRNA levels, the proportion of
the aggregated isoform may decrease providing PD-protection.
Additional assays directly measuring the association of the full and
spliced forms with SNPs in the 39 region will be required to settle
this question. Alternatively, acknowledging the contradictory
findings in the field with respect to ups and down regulation of
SNCA levels in PD brains [12,13,34–36] one cannot exclude the
interpretation that the association between the 39 SNPs and
sporadic PD is the result of lower SNCA expression levels.
Nevertheless, alteration in SNCA-mRNA levels might contribute
to disease pathogenesis in many but, perhaps, not all cases of
sporadic PD.
Our study examined several SNPs in various brain tissues for
association with expression, and as such, is subject to false positive
associations. Therefore, P values should be interpreted with
caution. After Bonferroni adjustment for 18 hypotheses (6 variants
x 3 tissues), the associations with all variants became non-
significant. However, given that these were not independent
hypotheses (brain tissues from the same individuals and with clear
correlation of expression, SNPs in linkage disequilibrium), this
may be an overly conservative interpretation. The results of this
study suggest an association between specific variants in SNCA and
expression that warrants further investigation in a larger cohort
such as a multi site meta analysis platform.
Our analysis included functionally and anatomically distinct
brain regions from unaffected age-matched brains. Frontal cortex,
temporal cortex, and substantia nigra are known to have
differential susceptibility to PD pathology, ranging from severely
afflicted substantia nigra, followed by temporal cortex that is
involved in a later stage, to the frontal cortex, which is a late-
developing structure that might be spared PD features [37].
Interestingly the genetic control identified in this study was not
global (across all brain regions) but brain-region specific, indicating
regionally differential regulation of SNCA-mRNA expression. Our
results show that, in relation to SNCA-mRNA overall expression
levels and genetic regulation, the temporal cortex mirrors the
substantia nigra. Thus, it is possible that these two brain regions
share regulatory mechanisms controlling SNCA expression. In
contrast, the frontal cortex showed lower SNCA-mRNA levels and
did not reflect the genetic regulation observed for the temporal
cortex and the midbrain including SN. Thus, concerning the
limited availability of substantia nigra region, temporal cortex may
serve as a surrogate brain region carry out further studies on
expression of SNCA and other genes in PD.
A critical question concerning the molecular pathogenesis of PD
is what role SNCA plays in sporadic PD. Several recent association
studies have demonstrated that genetic variability across the SNCA
locus is associated with susceptibility to sporadic PD in many
populations [14–17]. In this study, we demonstrated the functional
consequence of genetic variations in the SNCA genomic region and
showed that the genetic association of some variants correlates
with biological function, in particular regulation of SNCA
expression levels. This suggests that regulation of SNCA gene
expression levels might be important in the development of
sporadic PD in patients who do not express a mutated protein or
who do not have an increase in gene copy number. Given that
multiplications of SNCA have been implicated in familial PD, we
suggest that a subtle increase in SNCA expression over decades
confers an elevated risk for late-onset, sporadic PD.
The results of our study advanced our understanding of the
contribution of genetic variants within the SNCA locus to sporadic
PD. Better understanding the molecular mechanisms modulating
SNCA gene expression, may lead to novel therapeutic approaches
based on reductions in SNCA levels [38–40].
Materials and Methods
Brain Samples
Brain tissue samples, including midbrain/pons/substantia nigra
(n=34), temporal cortex (n=77), and frontal cortex (n=117),
from neurologically healthy controls (n=144) (Table 1) were
obtained through the Kathleen Price Bryan Brain Bank (KPBBB)
at Duke University, the Brain and Tissue Bank for developmental
Disorders at the University of Maryland, the Layton Aging &
Alzheimer’s Disease Center at Oregon Health and Science
University, and the National NeuroAIDS Tissue Consortium
(NNTC). All post mortem interval (PMI) were ,24 hours.
Demographics for these samples are included in Table 1. All
brain samples were collected from clinically and neuropatholog-
ically healthy cadavers who had no evidence of PD, AD or other
neurodegenerative disorder at post mortem examination.
DNA Extraction and Genotyping
Genomic DNA was extracted from brain tissues by the standard
Qiagen protocol. Genotype determination of each Single Nucle-
otide Polymorphism (SNP) was performed by allelic discrimination
using TaqMan SNP Genotyping Assays (Applied Biosystems,
Foster City, CA). Each genomic DNA sample (20 ng) was
amplified using TaqMan Universal PCR master mix reagent
(Applied Biosystems, Foster City, CA) combined with the specific
TaqMan SNP genotyping assay mix corresponding to the
genotyped SNP (Table S1). The assays were carried out using
the ABI 7900HT and the following conditions: 2 min at 50uC,
10 min at 95uC, 40 cycles: 15 sec at 95uC, and 1 min at 60uC.
Genotype determination was performed automatically using the
SDS version 2.2 Enterprise Edition Software Suite (Applied
Biosystems, Foster City, CA). SNCA-Rep1 dinucleotide complex
repeat polymorphism genotyping was carried out by size using
SNCA-mRNA-Genetic Regulation
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region of each genomic DNA sample (20 ng) was PCR-amplified
using fluorescently labeled forward FAM 59-CCTGGCATATTT-
GATTGCAA-39 and reverse 59-GACTGGCCCAAGATTA-
ACCA-39 primers [19]. Genotypes were determined on an ABI
3730 using GeneMapper version 4.0 software (Applied Biosystems,
Foster City, CA) for allelic size assessment. The Rep1 allele was
determined according to the length of the PCR product (259 bp,
261 bp, 263 bp and 265 bp). All genotypes were tested for Hardy-
Weinberg Equilibrium and allele frequencies compared to the
public database and previously published results (Tables 2 and 3).
RNA extraction and cDNA synthesis
Total RNA was extracted from brain samples (100 mg) using
TRIzol reagent (Invitrogen, Carlsbad, CA) followed by purifica-
tion with an RNeasy kit (Qiagen, Valencia, CA) following the
manufacturer’s protocol. RNA concentration was determined
spectrophotometrically at 260 nm, while the quality of the
purification was determined by 260 nm/280 nm ratio that showed
values between 1.9 and 2.1, indicating high RNA quality.
Additionally, quality of sample and lack of significant degradation
products was confirmed on an Agilent Bioanalyzer. The RNA
Integrity Number (RIN) measurements were greater than 7
validating the RNA quality control. Next, cDNA was synthesized
using MultiScribe RT enzyme (Applied Biosystems, Foster City,
CA) under the following conditions: 10 min at 25uC and 120 min
at 37uC.
Real time PCR
Real-time PCR was used to quantify human SNCA mRNA
levels as previously described [12]. Briefly, duplicates of each
sample were assayed by relative quantitative real-time PCR using
the ABI 7900 for analysis of the level of SNCA message as
compared in brain tissues to mRNA encoding human synapto-
physin (SYP), a presynaptic protein that has a similar expression
pattern to SNCA [12,30]. Each cDNA (10 ng) was amplified in
duplicate in at least two independent runs (overall$4 repeats),
using TaqMan Universal PCR master mix reagent (Applied
Biosystems, Foster City, CA) and the following conditions: 2 min
at 50uC, 10 min at 95uC, 40 cycles: 15 sec at 95uC, and 1 min at
60uC. The target SNCA cDNA was amplified using ABI MGB
probe and primer set assay ID Hs00240906_m1, normalized to a
SYP RNA control (ABI MGB probe and primer set assay ID
Hs00300531_m1) (Applied Biosystems, Foster City, CA). As a
negative control for the specificity of the amplification and to
control for DNA contamination, we used RNA control samples
that were not converted to cDNA (no-RT) and no-cDNA/RNA
samples (no-template) in each plate. No observable amplification
was detected. Data were analyzed with a threshold set in the linear
range of amplification. The cycle number at which any particular
sample crossed that threshold (Ct) was then used to determine
fold difference. Fold difference was calculated as 2
2DDCt;
DCt=[Ct(SNCA)-Ct (SYP)]. DDCt=[DCt(sample)]-[ DCt(calibra-
tor)]. The calibrator was a particular brain RNA sample used
repeatedly in each plate for normalization within and across runs.
The variation of the DCt values among the calibrator replicates
was smaller than 10%.
Of note is that three internal controls were compared: the neuronal
specific genes Enolase 2 (ENO2 Hs00157360_m1) and synaptophysin
(SYP Hs00300531_m1) and the house keeping gene glyceraldehydes-
3-phosphate dehydrogenase (GAPDH Hs00999905_m1). For assay
validation we generated standard curves for SNCA and each reference
assay, ENO2, SYP and GAPDH using different amounts of human
brain total RNA (0.1–100 ng). The slope of the relative efficiency plot
for SNCA and each internal control (ENO2 SYP or GAPDH)w a s
determined to validate the assays. The slope in the relative efficiency
plots for SNCA and the reference genes were .0.1, showing a
standard value required for the validation of the relative quantitative
method (Figure S1). In addition, for a subset of brain samples (for
each type of brain tissue) we used the geometric mean of SYP and
ENO2 and the GAPDH as normalization controls and confirmed the
selection of SYP as a representative normalization control for the
entire brain set. Thus, for the extended study we chose SYP as the
internal control.
Statistical analysis
SNCA-mRNA fold expression value of each sample was
analyzed repetitively and the results of all replicates were
averaged. All average values were expressed as mean6S.E.M.
Correlations were assessed by linear regression analyses. A log
transformation (log2) was performed on all mRNA levels to assure
normal distribution [42]. The general linear model (GLM) method
was used to evaluate the effect of the primary explained variable
(genotype) as well as other secondary variables (sex, age, PMI,
ethnicity, tissue source) on the RNA levels. The GLM is a
procedure unifying the ordinary linear regression and ANOVA as
well as other procedures based on the least square computation
such as ANCOVA. Since gender, age, PMI, ethnicity, and tissue
source may also show an effect on the RNA levels, they were
included in the model as factors. Where the P value of the
maximal model remains significant, an effect of each single term
was estimated calculating the type III sum of squares and the
corresponding F value and its probability P. Correction for
multiple testing employed the Bonferroni method. Tissues
comparisons were done by paired t-tests. All analyses were carried
out using STATA/IC10.0 statistical software (StataCorp, College
Station, TX).
The Bryan ADRC Autopsy and Brain Donation Program
Database/Repository has been granted approval from the Duke
University Health System Institutional Review Board for Clinical
Investigations, eIRB# Pro 00016278. Subject’s (or their Legally
Authorized Representatives) participating in the Bryan ADRC
Autopsy and Brain Donation Program Database/Repository have
provided written consent for use of their data and brain specimens
to be used for use in future research. The genetic and expression
analysis of all brain tissues obtained for this study is covered by
eIRB exemption #10141.
Supporting Information
Table S1 TAQMAN Genotyping Assays *Primers and probe
sequences available upon request.
Found at: doi:10.1371/journal.pone.0007480.s001 (0.03 MB
DOC)
Table S2 Discovery and Confirmatory Samples Sets. FC- frontal
cortex, TC-temporal cortex, SN-substantia nigra. PMI- post
mortem interval. Total no.- indicates the entire samples set used
in the initial discovery step (N=228; reference gene, SYP);
Replication- referrers to the subset of temporal cortex samples
used in the validation step (n=24; reference genes, SYP, ENO2
and GAPDH) to confirm key results.
Found at: doi:10.1371/journal.pone.0007480.s002 (0.03 MB
DOC)
Figure S1 Relative efficiency plots of SNCA and the reference
control genes. Validation curve of the Dreal time assay for relative
quantization of human SNCA-mRNA in brain relative to: (A)
SYP-mRNA, (B) ENO2-mRNA, and (C) GAPDH-mRNA.
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PLoS ONE | www.plosone.org 8 October 2009 | Volume 4 | Issue 10 | e7480Relative efficiency plots of SNCA and each of the normalization
control genes were formed by plotting the log input amount
(ng of total RNA) versus the DCt=[Ct(SNCA)-Ct(SYP/ENO2/
GAPDH)]. The slopes are all ,0.1, which indicated the validation
of the DCt calculation in the range between 0.1–100 ng RNA with
all three controls.
Found at: doi:10.1371/journal.pone.0007480.s003 (1.94 MB
DOC)
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